LGND
LIGAND PHARMACEUTICALSData as of 2026 Q2 (06-30) · 13F snapshot
Summary
LIGAND PHARMACEUTICALS (LGND) is held as common stock by 2 tracked hedge-fund managers, with a combined reported value of ~$2.40M; the largest are Izzy Englander, Joel Greenblatt. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 1 trimmed, 1 closed. 7 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · LowThis quarter · Quiet
Common-stock holders22 also report options
Congress trades7
Price$310.36vs quarter-end-1.81%
Sectors0
This quarter's moves
Top holderNew1
Added0
Trimmed / sold2
Izzy EnglanderCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $3.16M— of portfolio10,0002026 Q2
Value $537.4K— of portfolio1,7002026 Q2
Value $252.9K— of portfolio8002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $3.16M | — | — |
| Ken GriffinPUT | $537.4K | — | — |
| Steven CohenPUT | $252.9K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.